Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

[Biomarkers in Alzheimer's disease].

García-Ribas G, López-Sendón Moreno JL, García-Caldentey J.

Rev Neurol. 2014 Apr 1;58(7):308-17. Review. Spanish.

PMID:
24677154
[PubMed - indexed for MEDLINE]
Free Article
2.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

PMID:
23800368
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
[PubMed - indexed for MEDLINE]
4.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

PMID:
19296504
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
[PubMed - indexed for MEDLINE]
6.

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Engelborghs S, Le Bastard N.

Mol Diagn Ther. 2012 Jun 1;16(3):135-41. doi: 10.2165/11634170-000000000-00000.

PMID:
22646065
[PubMed - indexed for MEDLINE]
7.

A data-driven model of biomarker changes in sporadic Alzheimer's disease.

Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.

PMID:
25012224
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.

Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.

J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11.

PMID:
24237038
[PubMed - indexed for MEDLINE]
9.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

PMID:
21825215
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
[PubMed - indexed for MEDLINE]
11.

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Acta Neuropathol. 2011 May;121(5):597-609. doi: 10.1007/s00401-011-0808-0. Epub 2011 Feb 11.

PMID:
21311900
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1. Review.

PMID:
23642576
[PubMed - indexed for MEDLINE]
13.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
[PubMed - indexed for MEDLINE]
14.

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1340-54. doi: 10.1016/j.neurobiolaging.2010.04.030. Epub 2010 Jun 8.

PMID:
20570401
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.

Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O.

PLoS One. 2012;7(6):e38639. doi: 10.1371/journal.pone.0038639. Epub 2012 Jun 22.

PMID:
22761691
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.

Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.

J Alzheimers Dis. 2011;24(3):537-46. doi: 10.3233/JAD-2011-101878.

PMID:
21297262
[PubMed - indexed for MEDLINE]
17.

Longitudinal changes of CSF biomarkers in Alzheimer's disease.

Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.

J Alzheimers Dis. 2011;25(4):583-94. doi: 10.3233/JAD-2011-101911.

PMID:
21460434
[PubMed - indexed for MEDLINE]
18.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.

Acta Neurol Scand Suppl. 2003;179:47-51.

PMID:
12603251
[PubMed - indexed for MEDLINE]
19.

CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.

Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H.

Mol Psychiatry. 2014 Feb;19(2):148-9. doi: 10.1038/mp.2013.18. Epub 2013 Feb 19. No abstract available.

PMID:
23419830
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ.

Neurobiol Aging. 2012 Oct;33(10):2272-81. doi: 10.1016/j.neurobiolaging.2011.12.017. Epub 2012 Jan 20.

PMID:
22264648
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk